experimental group:Camrelizumab combined with apatinib

2 trials

Sponsors

Shanxi Tumor Hospital, Medical Institution

Conditions

Hepatocellular carcinomaLung Cancer

Phase 2

Clinical study of Camrelizumab combined with apatinib in the treatment of EGFR-TKI resistance in NSCLC

RecruitingChiCTR2000041118

Shanxi Tumor HospitalLung Cancer

Start: 2020-12-22Updated: 2021-03-01

Unknown Phase

Clinical study of Carrilizumab combined with Apatinib in prevention of postoperative recurrence of early hepatocellular carcinoma

Active, not recruitingChiCTR2500115863

Medical InstitutionHepatocellular carcinoma

Start: 2026-01-01Updated: 2026-01-05